Video
Dr. Galbraith Discusses Phase I/II Results for AZD9291 in Advanced NSCLC
Author(s):
Susan Galbraith, MD, PhD, head, Oncology Innovative Medicine, AstraZeneca, discusses updated data from the ongoing phase I/II AURA study looking at AZD9291 for NSCLC.
Susan Galbraith, MD, PhD, head, Oncology Innovative Medicine, AstraZeneca, discusses updated data from the ongoing phase I/II AURA study. This study aims to evaluate AZD9291 for patients previously treated with an EGFR TKI with advanced non-small cell lung cancer (NSCLC) with the T790M mutation.
The confirmed overall response rate was 70% in patients treated with 80 mg of AZD9291. Since the 2014 ASCO Annual Meeting, results have been updated to show that responses are durable — median PFS is 9.6 months. Currently, Galbraith says, the only option for this group of patients is chemotherapy, which elicits PFS of 3-4 months.
Galbraith also notes that AZD9291 is associated with reduced rates of rash and diarrhea compared with chemotherapy.
<<<
